KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Depreciation & Amortization (CF) (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Depreciation & Amortization (CF) for 16 consecutive years, with $322284.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 22.68% to $322284.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Dec 2025, down 20.1% year-over-year, with the annual reading at $1.4 million for FY2025, 20.1% down from the prior year.
  • Depreciation & Amortization (CF) hit $322284.0 in Q4 2025 for Inovio Pharmaceuticals, down from $350198.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $945200.0 in Q4 2021 to a low of $322284.0 in Q4 2025.
  • Historically, Depreciation & Amortization (CF) has averaged $623530.2 across 5 years, with a median of $651005.0 in 2021.
  • Biggest five-year swings in Depreciation & Amortization (CF): skyrocketed 40.67% in 2022 and later tumbled 39.99% in 2024.
  • Year by year, Depreciation & Amortization (CF) stood at $945200.0 in 2021, then dropped by 6.89% to $880041.0 in 2022, then plummeted by 35.27% to $569687.0 in 2023, then fell by 26.83% to $416821.0 in 2024, then fell by 22.68% to $322284.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for INO at $322284.0 in Q4 2025, $350198.0 in Q3 2025, and $356151.0 in Q2 2025.